Comparing the prognostic performance of iBOX and biopsy-proven acute rejection for long-term kidney graft survival-Reference-Cited by-同舟云学术

Comparing the prognostic performance of iBOX and biopsy-proven acute rejection for long-term kidney graft survival

Published:2024-04 Issue: Volume: Page:
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:American Journal of Transplantation

Author:

Klein Amanda^ORCID,Kosinski Luke^ORCID,Loupy Alexandre^ORCID,Frey Eric,Stegall Mark^ORCID,Helanterä Ilkka^ORCID,Newell Kenneth^ORCID,Meier-Kriesche Herwig-Ulf,Mannon Roslyn B.^ORCID,Fitzsimmons William E.^ORCID

Funder

U.S. Food and Drug Administration

Utah Department of Health and Human Services

U.S. Department of Health and Human Services

Publisher

Elsevier BV

Reference18 articles.

1. Committee for Medicinal Products for Human Use (CHMP) Guideline on Clinical Investigation of Immunosuppressants for Solid Organ Transplantation Draft Agreed by Efficacy Working Party End of Consultation (Deadline for Comments),2007

2. Acute rejection after kidney transplant-an endpoint not predictive of treatment effect on graft survival;Fitzsimmons;Transplantation,2024

3. Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204096s003s004lbl.pdf. Accessed 1 March 2024.

4. Highlights of Prescribing Information. These Highlights Do Not Include All the Information Needed to Use PROGRAF Safely and Effectively. See Full Prescribing Information for PROGRAF. PROGRAF (Tacrolimus) Capsules PROGRAF (Tacrolimus) Injection, (for Intravenous Use). https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050709s031lbl.pdf. Accessed 1 March 2024.

5. Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206406s007lbl.pdf. Accessed 1 March 2024.